signaling pathway was found to play a role in the development of certain types of cancers, such as gastric, colorectal and breast cancer including HCC. β-catenin is a key effector and plays a fundamental role in this pathway [10, 20] . In the absence of Wnt ligands, β-catenin is phosphorylated and degraded by a destruction complex which consists of adenomatous polyposis coli (APC), Axin, glycogen synthase kinase-3β (GSK3β) and casein kinase 1α [9, 15] . However, the presence of the ligand disrupts the destruction, allowing the unphosphorylated β-catenin to be translocated into the nucleus. Then, nuclear β-catenin binds to the TCF transcription factor and activates the expression of various genes such as c-Myc and Cyclin D1 which are needed to be involved in cell proliferation, cell migration and cell survival [11, 26] .
Bcl9 (B cell lymphoma 9 gene) and Pygopus are core components of β-catenin/TCF complex and indispensable to Wnt/β-catenin signaling. The domain structure of Bcl9 includes five homology domains (HD1 to HD5) where HD1 to HD3 are highly conserved between Drosophila, zebrafish and mammals [16] , whereas HD4 and HD5 are highly conserved among mice, humans and vertebrates [1] . Bcl9 is translocated to nucleus by Pygopus and functions as an adaptor protein between Pygopus and β-catenin [16] . Overexpression of Bcl9 increases cell proliferation, migration, invasion and metastatic potential of tumor cells and was reported in various types of tumors such as colorectal cancer, multiple myeloma and HCC [5, 21] .
Recent studies demonstrated the nuclear localization of Bcl9 in various tumors, such as multiple myeloma, breast cancer, colon carcinoma and HCC cells unlike their normal cell counterparts. This finding seems to be consistent with the function of Bcl9 as a co-activator of β-catenin in the nucleus. [18, 24] . However, Bcl9 was also reported to localize in both cytoplasm and nucleus, irrespective of the normal and malignant status of adrenocortical cells [6] . In addition, Bcl9 is known to be involved in enamel production and lens development, independently of β-catenin signalling [7, 8] . Consequently, the intracellular localization of Bcl9 is currently a controversial issue, mainly because it may form different complexes [25] , reflecting a different functional state. Therefore, for a better understanding of Bcl9 function, we need to analyse the different epitopes by immunohistochemistry.
In the present study, we mapped the localization of Bcl9 in Myanmar HCC immunohistochemically using two different antibodies. The anti-Bcl9 BIO antibody recognizes the Pygopus-binding domain of Bcl9, an epitope essential for the nuclear localization of Bcl9 and could be masked by the binding of Pygopus. The other one was anti-Bcl9 ABC , which can react with the different epitopes of Bcl9 and had been widely used in the previous studies [12, 30] . Finally, we analysed the expression profiles of Bcl9 in differentiation grades of Myanmar HCC and clinicopathological parameters to evaluate the diagnostic value of Bcl9.
II. Materials and Methods

Chemicals and antibodies
3-Aminopropyltriethoxysilane (APS), bovine serum albumin (BSA, essentially fatty acid-and globulin-free), 30% Brij ® L23 solution, normal goat IgG and rabbit IgG were purchased from Sigma-Aldrich (St. Louis, MO, USA). Normal mouse IgG was from Dako (Glostrup, Denmark). Mouse monoclonal anti-human Bcl9 (BMR00368; 2.0 μg/ml) was a gift from Bio Matrix Research Inc. (Nagareyama, Chiba, Japan) and rabbit polyclonal antihuman Bcl9 (ab37305; 5.0 μg/ml) was purchased from Abcam (Cambridge, MA, USA) [12, 30] . Mouse monoclonal anti-β-catenin (CTNNB1, UM500015; 1.33 μg/ml) was purchased from OriGene (Rockville, MD, USA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (AP308P; 10.0 μg/ml) and HRP-conjugated goat antirabbit IgG (AP307P; 10.0 μg/ml) antibodies were from Millipore (Temecula, CA, USA). 3,3'-Diaminobenzidine-4HCl (DAB) was from Dojin Chemical Co. (Kumamoto, Japan). Permount was purchased from Thermo Fisher Scientific (Hudson, NH, USA). All other reagents used in this study were from Wako Pure Chemicals (Osaka, Japan).
Clinical samples
Surgically resected liver tissues were collected from patients diagnosed with HCC, who were treated surgically at the Yangon Specialty Hospital (YSH), Myanmar and fixed with 10% formalin and embedded in paraffin using standard procedures. Normal liver samples, resected away from the tumor lesions were also collected and processed. A total of 52 liver specimens were collected (Age; 20-82 years, mean ± SD; 53.2 ± 9.1, 31 (60%) male and 21 (40%) female). Data on hepatitis B virus (HBV) and hepatitis C virus (HCV) were obtained by the rapid diagnostic test from Standard Diagnostics (SD, Inc., Abbott Laboratories, Chicago, IL, USA) for HBV (SD Bioline HBsAg) and HCV (SD Bioline HCV) ( Tables 1 and 2) .
Ethical approval for this study was obtained from the Ethics Review Committee of the Department of Medical Research, Yangon (Ethics/DMR/2018/059) and all liver specimens were collected after obtaining written informed consent of the patients in accordance with the Declaration of Helsinki.
Histopathological examination
Liver specimens were cut into 5 μm thickness serial sections and mounted on APS-coated slides. Using hematoxylin and eosin (H&E) stained slides, histopathological examination was conducted by two pathologists, blinded to the patients' basic and clinical data at Pathology Research Division, Department of Medical Research (DMR), Yangon using WHO classification [4] . The results were later confirmed by a Japanese pathologist who was also blinded to the clinical background. Of the 52 examined samples, 11 (21%) were considered normal liver and 41 (79%) 
Immunohistochemistry
Enzyme immunohistochemistry (IHC) was performed on paraffin sections of HCC as described previously [3, 17, 23] . All procedures were performed at room temperature. Briefly, the paraffin sections were deparaffinized with toluene and autoclaved in 10 mM citrate buffer (pH 6.0, 120°C for 15 min). Endogenous peroxidase was inactivated with 0.3% H 2 O 2 in methanol for 15 min. Then, the sections were preincubated with normal goat IgG (500 μg/ml) in 1% BSA in PBS for 1 h and then reacted with the primary antibody dissolved in 1% BSA in PBS for overnight. After washing three times with 0.075% Brij 35 in PBS for 10 min each, the sections were reacted with HRP-conjugated secondary antibody for 1 hr. Then, the sections were washed again with 0.075% Brij 35 in PBS and the sites of HRP were visualized with DAB and H 2 O 2 with nickel and cobalt ions. In each experimental run, the adjacent sections were reacted with normal mouse or rabbit IgG in the place of specific primary antibody and served as negative control. Finally, the sections were dehydrated and mounted.
Quantitative analysis
The stained slides were judged as positive or negative based on comparison with the negative control results. The staining intensity was graded as 0, 1, 2 and 3 representing negative, weak, moderate and strong staining, respectively, and used as immunohistochemical-score (IHC-score) for statistical analysis.
Statistical analysis
All data were expressed as mean ± SEM. The Wilcoxon-Mann-Whitney test was used for assessment of the statistical significance between age and sex groups. One-way ANOVA followed by Tukey's range test was used for comparison of statistical significance between histopathological classifications. P value < 0.05 denoted the presence of a statistically significant difference. All analyses were performed with KaleidaGraph 4 (Hulinks Inc., Tokyo, Japan).
III. Results
Immunohistochemical characterization of anti-Bcl9
BIO and anti-Bcl9
ABC antibodies
To discriminate the states of Bcl9, we used two antibodies that recognize different portions of Bcl9 as epitopes. One is a monoclonal anti-Bcl9 antibody from Bio Matrix Research Inc. (anti-Bcl9 BIO ), which was raised against the recombinant protein, no.50-200 amino acid (aa) residues of human-Bcl9 because the residue covers the major part of Pygopus-binding domain of Bcl9 (HD1, aa no.177-204) [24] , it was expected that the association of Pygopus with HD1 might disturb the binding of anti-Bcl9 BIO to Bcl9. The other was rabbit polyclonal anti-Bcl9 antibody purchased from Abcam (anti-Bcl9 ABC ), which was raised against synthetic peptide carrying aa no.800-900 of human-Bcl9, which is located near the N-terminus of HD4 (aa no.997-1048) of Bcl9. The latter had been used for immunohistochemical examination of tumors, including HCC, in previous studies reported by other groups [12, 30] (Fig. 1A) .
As shown in Fig. 1B , immunohistochemical staining using anti-Bcl9 BIO revealed the signals for Bcl9 mainly in the cytoplasm but not in the nuclei of well differentiated HCC cells. In comparison, immunostaining with antiBcl9 ABC detected the signals in either the cytoplasm or the nuclei, or both in adjacent serial sections that were used for anti-Bcl9 BIO . When we examined the expression of β-catenin, the signals was limited to the plasma membrane and no convincing co-localization with Bcl9. In addition, tissues stained with normal IgG in place of the primary antibody presented no staining.
Expression profile of Bcl9 detected by two antibodies in various types of histopathological grades of Myanmar HCC
Although overexpression of Bcl9 in the cytoplasm and nuclei was reported in HCC with the use of anti-Bcl9 ABC [18, 30] , our understanding of the functional status has been limited. To evaluate the biological significance of Bcl9 in HCC, we performed immunohistochemical staining using the two types of anti-Bcl9 antibodies in Myanmar HCC specimens and compared the expression profiles according to the histopathological differentiation grades. As shown in Fig. 2 , Bcl9 detected by anti-Bcl9 BIO was distinctively localized in the cytoplasm and the expression decreased with the progression of differentiation stage of HCC ( Fig. 2A) . Interestingly, localization of Bcl9 seemed to be restricted to certain areas of the cytoplasm especially in advanced HCC. On the other hand, the anti-Bcl9 ABC signal was detected mainly in the nucleus, but in some cases, a broad or uniform distribution of Bcl9 staining was noted in cytoplasm of HCC cells (Fig. 2A) . For statistical analysis, we used simple IHC-score (0, 1, 2, 3), which was determined by the signal intensity because most parts of the normal liver parenchyma and HCC nests were stained homogenously. The IHC-score of the normal liver stained with anti-Bcl9 BIO was significantly higher than that of any other differentiation stages of HCC (P < 0.01, Fig. 2B ). Moreover, IHC-score by anti-Bcl9 BIO tended to demonstrate inverse correlation with poorer differentiation grades of HCC. In contrast, the IHC-score by anti-Bcl9 ABC had no statistical significant differences among normal liver and various differentiation stages of HCC (P value, 0.535; Fig.  2B ).
Possible correlation between various clinicopathological parameters and Bcl9 expression
Finally, we analysed the clinicopathological features according to the IHC-score obtained with two types of antiBcl9 Involved in Juvenile HCC Bcl9 antibodies. Based on the recent study that identified Asians older than 40 years of age to be at highest risk of HCC among other populations [19] , we divided our HCC patients into two age groups; < 40 and ≥ 40 years and examined the differences in IHC-score. Very surprisingly, we found a significant difference in IHC-score obtained with anti-Bcl9 BIO between the two age groups (P value, 0.007, Fig. 3A) . When the age group was divided into < 45 and ≥ 45 years, significance was still identified (P value, 0.017), although no more significant difference (P value, 0.572) was noted when 50 years was used as the cut-off value. In contrast, the IHC-score with anti-Bcl9 (Fig. 3B-D) .
IV. Discussion
In the present study, we have found that the expression [12] . However, the expression of Bcl9 detected by anti-Bcl9 ABC in normal liver found in our study had a discrepancy from the previous reports where Bcl9 was not detected in normal liver [12, 30] . The difference might be due to the use of non-cancerous parts as normal liver in our study. Besides, almost 90% of our HCC specimens were positive to either HBV or HCV infection, suggesting that the difference could be also due to regenerating changes that could affect the expression of Bcl9.
Furthermore, statistical analysis of the expression profiles of Bcl9 detected by anti-Bcl9 ABC as well as β-catenin in our study failed to display any significant difference between normal liver parts and various differentiation stages of HCC. In this regard, previous study reported that β-catenin was localized in the nucleus in 35.3% of HCC cases [13] , whereas β-catenin was found mostly in the cytoplasm and plasma membrane of HCC cells in the present study and nuclear localization was detected only in 2 cases out of 41 cases. These discrepancies were probably due to the difference in pre-existing etiological factors in the developmental properties of Myanmar HCC, especially environmental inorganic toxic substances, such as iron, arsenic which have been reported to affect the pathogenesis of HCC [22, 28, 29] .
One important finding of this study was the significantly lower IHC-score with anti-Bcl9 BIO < 40 years age group (Fig. 3A) . This finding suggests that in the younger HCC cases including juvenile HCC, almost all Bcl9 would be activated and translocated into the nucleus by binding to Pygopus, depleting the cytoplasmic reservoir of Bcl9. Consequently, this could result in combinational imbalance of β-catenin machinery, leading to the promotion of the juvenile HCC development in Myanmar patients. Although the cytoplasmic expression of Bcl9 seems to be a new hepatological parameter, further studies with human and animal model specimens are needed to draw a solid conclusion about the role of Bcl9 in the juvenile development of HCC.
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